Association among the expression of β-catenin, cyclin D1 and estrogen receptor-β in human breast cancer

Guo,Liying; Yilamu,Dilimina; Sun,Liting; Liu,Sha; Ma,Fangjing

doi:10.3892/etm.2015.2657

Association among the expression of β-catenin, cyclin D1 and estrogen receptor-β in human breast cancer

Authors:
- Liying Guo
- Dilimina Yilamu
- Liting Sun
- Sha Liu
- Fangjing Ma
View Affiliations

Affiliations: Department of Breast Cancer, Digestive and Vascular Center, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China
Published online on: July 27, 2015 https://doi.org/10.3892/etm.2015.2657
Pages: 1423-1428

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

β-catenin, cyclin D1 and estrogen receptor (ER)-β are closely associated with the pathogenesis of breast cancer. In the present study, tissue samples were collected from 226 patients with breast cancer. Subsequently, immunohistochemical analysis was performed to detect the expression of β‑catenin, cyclin D1 and ER‑β, and the Kaplan‑Meier method was used for survival analysis. The abnormal expression rate of β‑catenin was 75.2%, while the cyclin D1 positive expression rate was 77.0% and the ER‑β positive expression rate was 43.4%. In the tissue samples exhibiting abnormal expression of β‑catenin, the positive expression rate of cyclin D1 (85.9%) was significantly higher compared with the samples that expressed β‑catenin normally (50.0%). Furthermore, the positive expression rate of ER‑β (35.7%) in the β‑catenin normal expression tissues was significantly lower compared with that in the β‑catenin abnormal expression tissues (45.9%). In the tissues with positive cyclin D1 expression, the positive expression rate of ER‑β (48.4%) was significantly higher compared with the cyclin D1 negative expression samples (26.9%). In addition, patients with normal expression of β‑catenin and positive expression of cyclin D1 exhibited longer tumor‑free survival times. Therefore, an association exists among the abnormal expression of β‑catenin and the positive expression of cyclin D1 and ER-β, which may contribute to the development of breast cancer.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Kohlberger PD, Breitenecker F, Kaider A, Lösch A, Gitsch G, Breitenecker G and Kieback DG: Modified truecolor computer-assisted image analysis versussubjective scoring of estrogen receptor expression in breast cancer: A comparison. Anticancer Res. 19:2189–2193. 1999.PubMed/NCBI
3	Kikuchi A: Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun. 268:243–248. 2000. View Article : Google Scholar : PubMed/NCBI
4	Mauro L, Pellegrino M, Giordano F, Ricchio E, Rizza P, De Amicis F, Catalano S, Bonofiglio D, Panno ML and Andò S: Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells. FASEB J. 29:2150–2160. 2015. View Article : Google Scholar : PubMed/NCBI
5	Luo J, Chen YL and Xu H: Expression of β-catenin, cyclin D1 and ERα in breast cancer. Shi Yong Yu Fang Yi Xue. 17:1502–1504. 2010.(In Chinese).
6	Kuiper GG, Enmark E, PeltoHuikko M, Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925–5930. 1996. View Article : Google Scholar : PubMed/NCBI
7	Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN and Atkin SL: Coexpression of estrogen receptor α and β: Poor progonostic factors in human breast cancer. Cancer Res. 59:525–528. 1999.PubMed/NCBI
8	Speirs V, Adams IP, Walton DS and Atkin SL: Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland. J Clin Endocrinol Metab. 85:1601–1605. 2000. View Article : Google Scholar : PubMed/NCBI
9	Howe LR and Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther. 3:36–41. 2004. View Article : Google Scholar : PubMed/NCBI
10	Bala S and Peltomäki P: CYCLIN D1 as a genetic modifier in hereditary non polyposis colorectal cancer. Cancer Res. 61:6042–6045. 2001.PubMed/NCBI
11	Lim SC and Lee MS: Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep. 9:915–928. 2002.PubMed/NCBI
12	Lin SY, Xia W, Wang JC, et al: Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 97:4262–4266. 2000. View Article : Google Scholar : PubMed/NCBI
13	Brabletz T, Jung A, Reu S, et al: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
14	Paola C, Anna P, Marina R, Gnesi E, Baldini E and Bevilacqua G: Cyclin D1 expression in node positive (N+) and node-negative (N-) infiltrating human mammary carcinomas. Int J Cancer. 84:139–144. 1999. View Article : Google Scholar : PubMed/NCBI
15	Ozaki S, Ikeda S, Ishizaki Y, et al: Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep. 14:1437–1443. 2005.PubMed/NCBI
16	Yang JF, Chen SL, Liu ZH and Zhang Y: Correlation among expression of E-cadherin, beta-catenin, and cyclin D1 in breast cancers. Ai Zheng. 23:799–802. 2004.(In Chinese). PubMed/NCBI
17	Lazennec G, Bresson D, Lucas A, Chauveau C and Vignon F: ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 142:4120–4130. 2001. View Article : Google Scholar : PubMed/NCBI
18	CastroRivera E, Samudio I and Safe S: Estrogen regulation of cyclin D1 gene expression in ZP-75 breast cancer cells involves multiple enhancer elements. J Biol Chem. 276:30853–30861. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ravikumar G and Ananthamurthy A: Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. J Cancer Res Ther. 10:671–675. 2014.PubMed/NCBI
20	Zwijsen R, Wientjens E, Klompmaker R, van der Sman J, Bernards R and Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell. 88:405–415. 1997. View Article : Google Scholar : PubMed/NCBI
21	Musgrove EA: Wnt signaling via the epidermal growth factor receptor: A role in breast cancer? Breast Cancer Res. 6:65–68. 2004. View Article : Google Scholar : PubMed/NCBI
22	Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, Markaki S and Keramopoulos A: Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol. 19:556–563. 2006. View Article : Google Scholar : PubMed/NCBI
23	López-Knowles E, Zardawi SJ, McNeil CM, et al: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 19:301–309. 2010. View Article : Google Scholar : PubMed/NCBI
24	Chung GG, Zerkowski MP, Ocal IT, et al: beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer. 100:2084–2092. 2004. View Article : Google Scholar : PubMed/NCBI
25	Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G and Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 69:92–99. 1996. View Article : Google Scholar : PubMed/NCBI
26	Steeg PS and Zhou Q: Cyclins and breast cancer. Breast Cancer Res Treat. 52:17–28. 1998. View Article : Google Scholar : PubMed/NCBI
27	Diana M and Barnes CEG: Cyclin D1 in breast cancer. Acta Oncology. 24:4211995.
28	Bates S, Parry D, Bonetta L, Vousden K, Dickson C and Peters G: Absence of cyclin D/CDK complexes in cells lacking functional retinoblastoma protein. Oncogene. 9:1633–1640. 1994.PubMed/NCBI
29	Quintayo MA, Munro AF, Thomas J, et al: GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients. Breast Cancer Res Treat. 136:161–168. 2012. View Article : Google Scholar : PubMed/NCBI
30	Peurala E, Koivunen P, Haapasaari KM, Bloigu R and Jukkola-Vuorinen A: The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res. 15:R52013. View Article : Google Scholar : PubMed/NCBI